ClinicalTrials.gov posted results on 2026-08-03 for semaglutide in NCT05548647, a completed phase 4 study in obesity. The 120-participant trial assessed long-term effects on appetite and eating behavior versus placebo, with lifestyle counseling given to all participants.
Background
The study tested semaglutide 2.4 mg/0.75 ml subcutaneous solution [Wegovy] against placebo in adults with obesity. The posted brief summary says the trial evaluated effects on eating behavior, hunger and fullness, and food liking over 72 weeks.
Trial design
This was a randomized, placebo-controlled study with 120 participants. The record lists lifestyle modification counseling for all participants and two intervention arms: placebo and semaglutide. Posted analyses compared mean change at week 20, week 40, and week 60 controlling for baseline values.
Key results
For ad libitum energy intake during a buffet lunch meal, the semaglutide group showed lower intake change than placebo at multiple time points. The posted ANCOVA net mean difference was 291.9 kcal (95% CI 164.0 to 419.8; p=0.0001) at week 20, 240.2 kcal (95% CI 65.2 to 415.3; p=0.0078) at week 40, and 269.5 kcal (95% CI 102.8 to 436.1; p=0.0019) at week 60.
For laboratory-based appetite measured as a composite of visual analogue scale ratings, the posted net mean difference was -12.1 mm (95% CI -18.6 to -5.6; p=0.0004) at week 20, -7.4 mm (95% CI -15.6 to 0.9; p=0.0784) at week 40, and -1.0 mm (95% CI -8.9 to 7.0) at week 60.
What this means
The posted results add long-term trial data to semaglutide’s obesity evidence base. In this study, the semaglutide arm showed lower buffet energy intake and an early appetite signal versus placebo, although the appetite composite was not consistently different across later time points.
Source
This information is based on ClinicalTrials.gov results posted for NCT05548647 on 2026-08-03. The record is available at clinicaltrials.gov.